LAS VEGAS SANDS CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that LAS VEGAS SANDS CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.65B | Feb 6, 2026 |
| FY2025 | Sep 30, 2025 | $3.33B | Feb 6, 2026 |
| FY2025 | Jun 30, 2025 | $3.18B | Feb 6, 2026 |
| FY2025 | Mar 31, 2025 | $2.86B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $2.90B | Feb 6, 2026 |
| FY2025 | Sep 30, 2024 | $2.68B | Feb 6, 2026 |
| FY2025 | Jun 30, 2024 | $2.76B | Feb 6, 2026 |
| FY2025 | Mar 31, 2024 | $2.96B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $2.92B | Feb 7, 2025 |
| FY2024 | Sep 30, 2023 | $2.80B | Feb 7, 2025 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $3.44B | Feb 23, 2018 |
| FY2017 | Sep 30, 2017 | $3.20B | Feb 23, 2018 |
| FY2017 | Jun 30, 2017 | $3.14B | Feb 23, 2018 |
| FY2017 | Mar 31, 2017 | $3.11B | Feb 23, 2018 |
| FY2017 | Dec 31, 2016 | $3.08B | Feb 23, 2018 |
| FY2017 | Sep 30, 2016 | $2.97B | Feb 23, 2018 |
| FY2017 | Jun 30, 2016 | $2.65B | Feb 23, 2018 |
| FY2017 | Mar 31, 2016 | $2.72B | Feb 23, 2018 |
| FY2016 | Dec 31, 2015 | $2.86B | Feb 24, 2017 |
| FY2016 | Sep 30, 2015 | $2.89B | Feb 24, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $395.00M | Feb 6, 2026 |
| FY2025 | Sep 30, 2025 | $419.00M | Feb 6, 2026 |
| FY2025 | Jun 30, 2025 | $461.00M | Feb 6, 2026 |
| FY2025 | Mar 31, 2025 | $352.00M | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $324.00M | Feb 6, 2026 |
| FY2025 | Sep 30, 2024 | $275.00M | Feb 6, 2026 |
| FY2025 | Jun 30, 2024 | $353.00M | Feb 6, 2026 |
| FY2025 | Mar 31, 2024 | $494.00M | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $382.00M | Feb 7, 2025 |
| FY2024 | Sep 30, 2023 | $380.00M | Feb 7, 2025 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $707.00M | Feb 6, 2026 |
| FY2025 | Sep 30, 2025 | $719.00M | Feb 6, 2026 |
| FY2025 | Jun 30, 2025 | $783.00M | Feb 6, 2026 |
| FY2025 | Mar 31, 2025 | $609.00M | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $590.00M | Feb 6, 2026 |
| FY2025 | Sep 30, 2024 | $504.00M | Feb 6, 2026 |
| FY2025 | Jun 30, 2024 | $591.00M | Feb 6, 2026 |
| FY2025 | Mar 31, 2024 | $717.00M | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $710.00M | Feb 7, 2025 |
| FY2024 | Sep 30, 2023 | $688.00M | Feb 7, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $269.00M | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $228.00M | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $205.00M | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $143.00M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $109.00M | Feb 7, 2024 |
| FY2010 | Dec 31, 2010 | $1.78M | Mar 30, 2011 |
| FY2010 | Dec 31, 2009 | $533.0K | Mar 30, 2011 |
| FY2010 | Dec 31, 2008 | $12.79M | Mar 30, 2011 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.19B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $1.15B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $1.11B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $936.00M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $831.00M | Feb 7, 2024 |
| FY2022 | Dec 31, 2020 | $798.00M | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | $1.12B | Feb 4, 2022 |
| FY2020 | Dec 31, 2018 | $1.48B | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $1.42B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $1.29B | Feb 22, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.02B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $3.20B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $3.23B | Feb 6, 2026 |
| FY2020 | Dec 31, 2020 | ($1.31B) | Feb 5, 2021 |
| FY2020 | Dec 31, 2019 | $3.04B | Feb 5, 2021 |
| FY2020 | Dec 31, 2018 | $4.70B | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $4.54B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $4.04B | Feb 22, 2019 |
| FY2013 | Dec 31, 2013 | $4.44B | Feb 28, 2014 |
| FY2013 | Dec 31, 2012 | $3.06B | Feb 28, 2014 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.17B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $1.57B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $1.02B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $651.00M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $828.00M | Feb 7, 2024 |
| FY2022 | Dec 31, 2020 | $1.23B | Feb 3, 2023 |
| FY2021 | Dec 31, 2019 | $1.02B | Feb 4, 2022 |
| FY2020 | Dec 31, 2018 | $949.00M | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $837.00M | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $1.40B | Feb 22, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.92B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $20.67B | Feb 6, 2026 |
| FY2025 | Dec 31, 2023 | $21.78B | Feb 6, 2026 |
| FY2024 | Dec 31, 2022 | $22.04B | Feb 7, 2025 |
| FY2022 | Dec 31, 2021 | $20.06B | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $20.81B | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $23.20B | Feb 5, 2021 |
| FY2020 | Dec 31, 2018 | $22.55B | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $20.69B | Feb 7, 2020 |
| FY2018 | Dec 31, 2016 | $20.47B | Feb 22, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.99B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $17.51B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $17.67B | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $18.38B | Feb 7, 2024 |
| FY2022 | Dec 31, 2021 | $17.81B | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $17.27B | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $16.69B | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $15.80B | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $13.06B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $12.97B | Feb 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.59B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $2.88B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $4.12B | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $3.88B | Feb 7, 2024 |
| FY2022 | Dec 31, 2021 | $2.00B | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $2.97B | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $5.19B | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $5.68B | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $6.49B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $6.18B | Feb 23, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.00M | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $102.00M | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $103.00M | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $10.00M | Feb 7, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.39B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $3.46B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $2.60B | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $1.68B | Feb 7, 2024 |
| FY2022 | Dec 31, 2021 | ($148.00M) | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $813.00M | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $3.10B | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $2.77B | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $2.71B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $2.22B | Feb 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.84B | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | $3.65B | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | $5.11B | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $6.31B | Feb 7, 2024 |
| FY2022 | Dec 31, 2021 | $1.85B | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | $2.08B | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | $4.23B | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $4.65B | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | $2.42B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $2.13B | Feb 23, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 6, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Feb 6, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Feb 6, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 6, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Feb 6, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Feb 6, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 7, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Feb 7, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 6, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Feb 6, 2026 |
| FY2025 | Jun 30, 2025 | 0 | Feb 6, 2026 |
| FY2025 | Mar 31, 2025 | 0 | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 6, 2026 |
| FY2025 | Sep 30, 2024 | 0 | Feb 6, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Feb 6, 2026 |
| FY2025 | Mar 31, 2024 | 0 | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 7, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Feb 7, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 675.00M | Feb 6, 2026 |
| FY2025 | Dec 31, 2024 | 716.00M | Feb 6, 2026 |
| FY2024 | Dec 31, 2023 | 753.00M | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | 764.00M | Feb 7, 2024 |
| FY2022 | Dec 31, 2021 | 764.00M | Feb 3, 2023 |
| FY2021 | Dec 31, 2020 | 764.00M | Feb 4, 2022 |
| FY2020 | Dec 31, 2019 | 764.00M | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | 775.00M | Feb 7, 2020 |
| FY2018 | Dec 31, 2017 | 789.00M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | 795.00M | Feb 23, 2018 |